We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]
Researchers improved etifoxine using deuteration technology by reducing its dosing requirements. The US patent to the new and improved etifoxine issued on September 25, 2018.
Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet
Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse [...]
Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial Dan J. Stein
A French study in 2009 found that Etifoxine was safe to drive on, classify it as Level 1 for the purposes of driving a vehicle.
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin
French researchers discovered that etifoxine has a dual mechanism of action: A) it works at GABA channels, and B) it increases neurosteroids more effectively than any other known compound.
A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects J. Micallef, C. Soubrouillarda, F. Gueta, M. E. Le Guernb, C. Alquierb, B. Bruguerollea, O. Blin
Etifoxine's patents expired during the mid 1980's, before the drug's true efficacy or mechanism of action was discovered. This explains why Etifoxine was never introduced into the United States or other major markets.
